Market Overview

Stull, Stull & Brody Launches Investigation Into Possible Breaches of Fiduciary Duty by the Board of Directors of Receptos, Inc.


NEW YORK, July 22, 2015 (GLOBE NEWSWIRE) -- Stull, Stull & Brody ( announces that a class action has been filed and that it is investigating potential claims on behalf of shareholders of Receptos, Inc. (NASDAQ: RCPT) ("Receptos" or the "Company") concerning whether the Company's Board of Directors breached its fiduciary duty by entering into an agreement and plan of merger under which all of the Company's outstanding shares will be acquired by Celgene Corporation for $232.00 per share in cash.

The current investigation is focused upon whether the Company's Board of Directors breached its fiduciary duty to maximize value to the Company's shareholders and to act in shareholders' best interests, including whether the Board of Directors undertook an adequate sales process and disclosed all material information to the Company's shareholders.

While the terms of the proposed transaction provide that the Company's shareholders will receive $232.00 per share in cash, at least one analyst has set a target price of $348.00 per share for the Company's stock.

Shareholders of Receptos may contact Michael J. Klein, Esq. at Stull, Stull & Brody to discuss their rights in connection with the proposed transaction by calling 1-800-337-4983, extension 147, or by email at

Stull, Stull & Brody has represented shareholders in merger litigation and other securities class actions for over 40 years and has obtained court approval of substantial settlements on numerous occasions.

Attorney Advertising.  Prior Results Do Not Guarantee a Similar Outcome.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at